[HTML][HTML] Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
D Ren, Y Hua, B Yu, X Ye, Z He, C Li, J Wang, Y Mo… - Molecular cancer, 2020 - Springer
Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.
D Ren, Y Hua, B Yu, X Ye, Z He, C Li, J Wang… - Molecular …, 2020 - europepmc.org
Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …
[PDF][PDF] Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
D Ren, Y Hua, B Yu, X Ye, Z He, C Li, J Wang, Y Mo… - 2020 - d-nb.info
Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
D Ren, Y Hua, B Yu, X Ye, Z He, C Li… - Molecular …, 2020 - pubmed.ncbi.nlm.nih.gov
Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …
[引用][C] Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
D Ren, Y Hua, B Yu, X Ye, Z He, C Li, J Wang, Y Mo… - Molecular Cancer, 2020 - Springer
Correction to: Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1
blockade cancer immunotherapy Page 1 CORRECTION Open Access Correction to: Predictive …
blockade cancer immunotherapy Page 1 CORRECTION Open Access Correction to: Predictive …
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
D Ren, Y Hua, B Yu, X Ye, Z He, C Li, J Wang, Y Mo… - Molecular …, 2020 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Immune checkpoint blockade targeting PD-
1/PD-L1 has promising therapeutic efficacy in a variety of tumors, but resistance during …
1/PD-L1 has promising therapeutic efficacy in a variety of tumors, but resistance during …
[HTML][HTML] Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
D Ren, Y Hua, B Yu, X Ye, Z He, C Li, J Wang… - Molecular …, 2020 - ncbi.nlm.nih.gov
Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.
D Ren, Y Hua, B Yu, X Ye, Z He, C Li… - Molecular …, 2020 - search.ebscohost.com
Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
D Ren, Y Hua, B Yu, X Ye, Z He, C Li, J Wang, Y Mo… - Molecular Cancer, 2020 - osti.gov
Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …
[HTML][HTML] Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy
D Ren, Y Hua, B Yu, X Ye, Z He… - Molecular …, 2020 - molecular-cancer.biomedcentral …
Immune checkpoint blockade targeting PD-1/PD-L1 has promising therapeutic efficacy in a
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …
variety of tumors, but resistance during treatment is a major issue. In this review, we describe …